Unknown

Dataset Information

0

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.


ABSTRACT: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of the still dismal prognosis, further improvements are desperately needed, especially in the patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors, in which the benefit of standard treatment is less. Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor (AK-DACi) molecule that fuses the DNA damaging effect of bendamustine with the fully functional pan-histone deacetylase (HDAC) inhibitor, vorinostat, in a completely new chemical entity.Tinostamustine has been tested in models of GBM by using 13 GBM cell lines and seven patient-derived GBM proliferating/stem cell lines in vitro. U87MG and U251MG (MGMT negative), as well as T98G (MGMT positive), were subcutaneously injected in nude mice, whereas luciferase positive U251MG cells and patient-derived GBM stem cell line (CSCs-5) were evaluated the orthotopic intra-brain in vivo experiments.We demonstrated that tinostamustine possesses stronger antiproliferative and pro-apoptotic effects than those observed for vorinostat and bendamustine alone and similar to their combination and irrespective of MGMT expression. In addition, we observed a stronger radio-sensitization of single treatment and temozolomide used as control due to reduced expression and increased time of disappearance of ?H2AX indicative of reduced signal and DNA repair. This was associated with higher caspase-3 activation and reduction of RT-mediated autophagy. In vivo, tinostamustine increased time-to-progression (TTP) and this was additive/synergistic to RT. Tinostamustine had significant therapeutic activity with suppression of tumor growth and prolongation of DFS (disease-free survival) and OS (overall survival) in orthotopic intra-brain models that was superior to bendamustine, RT and temozolomide and showing stronger radio sensitivity.Our data suggest that tinostamustine deserves further investigation in patients with glioblastoma.

SUBMITTER: Festuccia C 

PROVIDER: S-EPMC5830080 | biostudies-other | 2018 Feb

REPOSITORIES: biostudies-other

altmetric image

Publications

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Festuccia Claudio C   Mancini Andrea A   Colapietro Alessandro A   Gravina Giovanni Luca GL   Vitale Flora F   Marampon Francesco F   Delle Monache Simona S   Pompili Simona S   Cristiano Loredana L   Vetuschi Antonella A   Tombolini Vincenzo V   Chen Yi Y   Mehrling Thomas T  

Journal of hematology & oncology 20180227 1


<h4>Background</h4>The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of the still dismal prognosis, further improvements are desperately needed, especially in the patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors, in which the benefit of standard treatment is less. Tinostamustine (EDO-S101) is a first-in-class al  ...[more]

Similar Datasets

| S-EPMC4482855 | biostudies-other
2023-02-06 | ST002467 | MetabolomicsWorkbench
| S-EPMC7013996 | biostudies-literature
| S-EPMC3158014 | biostudies-literature
| S-EPMC4467398 | biostudies-literature
| S-EPMC4282784 | biostudies-literature
| S-EPMC8582824 | biostudies-literature
2015-03-18 | GSE62460 | GEO
| S-EPMC2944185 | biostudies-literature
| S-EPMC7718436 | biostudies-literature